EBIT at other companies
Other financials
Where this comes from
Calculated from Corvus Pharmaceuticals’s reported figures.
Plus components not separately reported this period.
The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corvus Pharmaceuticals's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corvus Pharmaceuticals's EBIT?
- Corvus Pharmaceuticals (CRVS) reported EBIT of -$14.88M in Q1 2026.
- How has Corvus Pharmaceuticals's EBIT changed year-over-year?
- Corvus Pharmaceuticals's EBIT decreased by 49.9% year-over-year, from -$9.92M to -$14.88M.
- What is the long-term trend for Corvus Pharmaceuticals's EBIT?
- Over 4 years (2021 to 2025), Corvus Pharmaceuticals's EBIT has grown at a 2.7% compound annual growth rate (CAGR), from -$38.63M to -$42.97M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.